All In MedTech

FDA Clearance Tracker · P020014-S039

ESSURE SYSTEM

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Dec 20, 2012 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Dec 20, 2012

Approved

Time to decision

31 days

Received Nov 19, 2012. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P020014-S039
Device name
ESSURE SYSTEM
Applicant location
Berlin
Received
Nov 19, 2012
Decided
Dec 20, 2012
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol - OSB
Original approval
P020014

Device type

Device class
Class III
Regulation
21 CFR 884.5380

Every decision under product code HHS

FDA's approval statement

As written in FDA's record.

APPROVAL OF THE POST-APPROVAL STUDY PROTOCOL.

Source documents

Other decisions for Bayer Pharma AG

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.